Decoding the molecular landscape: HER2 and PD-L1 in advanced gastric cancer
Overall, our study highlights the prognostic significance of <i>HER2</i> amplification and TP53 mutations in patients with advanced GC. Stratified analysis of PD-L1 expression may help to identify candidates for targeted immunotherapy in this patient population.
Authors
- Jieyi Li (ORCID: https://orcid.org/0000-0003-2881-2281)
- Xiaokai Zhao
- Meiping Gu
- Xintao Wang (ORCID: https://orcid.org/0009-0002-8213-0556)
- Daoyun Zhang
- Yuansi Zheng (ORCID: https://orcid.org/0000-0002-1360-3172)
- Pengmin Yang (ORCID: https://orcid.org/0000-0003-2472-3441)
- Han Wu (ORCID: https://orcid.org/0000-0001-9764-1063)
- Jun Yao (ORCID: https://orcid.org/0000-0002-3472-1602)
- Weijun Wang (ORCID: https://orcid.org/0000-0001-6907-2561)
- Qiang Sun (ORCID: https://orcid.org/0000-0003-2479-1137)
- Xiaozhi Wang
- Ziying Gong (ORCID: https://orcid.org/0000-0003-2619-6446)
Institutions
- Second Military Medical University (CN)
- Jiaxing University (CN)
- Zhejiang Cancer Hospital (CN)
- Shanghai Changzheng Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-05-30
- DOI
- https://doi.org/10.3389/fimmu.2025.1567308
- Citations
- 3
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 4.56